LL-37: Natural Defense, Experimental Treatment
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

LL-37 is a human antimicrobial peptide involved in innate defense. Researchers also study its effects on inflammation and wound biology, which makes the story more complex than a natural antibiotic label. A phase two-b trial tested topical LL-37 alongside compression care in 148 people with difficult venous leg ulcers. The overall study did not find a significant healing advantage over placebo. An analysis performed afterward suggested a signal in larger ulcers. That is a reason to test a hypothesis, not to replace the study’s overall result. Those findings also do not establish that injected LL-37 treats infections. FDA highlights safety uncertainty. A molecule’s normal role in the body cannot substitute for treatment evidence.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Mahlapuu et al. (2021): Randomized phase IIb LL-37 venous-leg-ulcer trial
https://pubmed.ncbi.nlm.nih.gov/34687253/
Primary human randomized trial

[2] FDA peptide safety information: Cathelicidin LL-37
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
US regulator

EVIDENCE LIMITATIONS
Post hoc subgroup findings require prospective confirmation.
Both trial groups received compression treatment; do not attribute standard-care effects to LL-37.
Topical wound research is not evidence for injected anti-infective use.
A favorable short trial tolerability finding cannot establish broad or long-term safety.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/936461545818337/